Matrix metalloproteinase 9 variation in erosive oral lichen planus before and after treatment
Phase 2
- Conditions
- erosive oral lichen planus.Other lichen planus
- Registration Number
- IRCT2016071728963N1
- Lead Sponsor
- Vice Chancellor for research of Shahid Beheshti University of Medical Science
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 20
Inclusion Criteria
Patients with erosive oral lichen planus with clinical and pathological confirmation whom need treatment. Exclusion criteria: Cutaneous lichen planus; Drug lichenoid reaction; Contact lichenoid reaction.
Exclusion Criteria
Not provided
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Matrix metalloproteinase 9. Timepoint: before and after treatment. Method of measurement: ELIASA technique.
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie MMP-9 variation in erosive oral lichen planus following triamcinolone mouthwash treatment?
How does triamcinolone mouthwash compare to standard corticosteroid therapies in managing erosive oral lichen planus?
Are specific MMP-9 biomarker profiles predictive of treatment response in erosive oral lichen planus patients using triamcinolone mouthwash?
What are the potential adverse events associated with triamcinolone mouthwash in erosive oral lichen planus treatment and how are they managed?
What combination therapies or alternative drugs show promise in targeting MMP-9 pathways for erosive oral lichen planus management?